Biotechnology News and Research

RSS

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.

20 Oct 2009

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Elan Corporation, plc and Biogen Idec today announced multiple presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 23-28 in San Diego.

20 Oct 2009

Biomagnetics Diagnostics to raise $1 million

Biomagnetics Diagnostics Corp. (Pink Sheets:BMGP), a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced the completion of its equity financing designed to fund entry into the Integrated Optical Biosensor Systems (IOBS) market.

20 Oct 2009

RA patients who adhere to their prescription drug regimen have better outcome: Study

Rheumatoid arthritis (RA) patients who regularly adhere to their prescription drug regimen have fewer emergency room and doctor visits and incur lower medical costs, according to research presented today by Medco Health Solutions, Inc. at the American College of Rheumatology's Annual Meeting in Philadelphia.

20 Oct 2009

Patheon, Lonza Group mutually agree to terminate discussions

The Special Committee of Independent Directors of Patheon Inc. today announced that Lonza Group AG ("Lonza") has withdrawn its previously announced non-binding proposal to acquire all of the outstanding restricted voting shares of the Company. In addition, the Special Committee and Lonza have mutually agreed to terminate discussions regarding other possible strategic transactions between Lonza and Patheon.

20 Oct 2009

Bio-Bridge Science receives business license for Bio-Bridge JRS Biosciences (Beijing)

Bio-Bridge Science, Inc., a biotechnology company engaged in the commercial development of vaccines and vaccine-related products announced today that the Company received a business license from the Beijing Administration for Industry and Commerce of the People’s Republic of China (“PRC”) indicating approval of the formation of Bio-Bridge JRS Biosciences (Beijing) Co., Ltd. (“Bio-Bridge JRS”).

20 Oct 2009

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

America's pharmaceutical research and biotechnology companies are working on nearly 1,000 life-changing medicines for diseases affecting women, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). The medicines are awaiting approval by the U.S. Food and Drug Administration or are in human clinical trials.

20 Oct 2009

Medidata Solutions extends multi-year contract with Bristol-Myers Squibb

Medidata Solutions, a global provider of hosted clinical development solutions, today announced a multi-year contract extension with Bristol-Myers Squibb Company for use of Medidata Grants Manager™, an investigator site benchmarking tool that helps sponsors ensure fair and consistent investigator payments, mitigate compliance risks and reduce trial start-up time.

19 Oct 2009

Encorium Group raises $1.6 million through private placement

Encorium Group, Inc., a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has completed a private placement of 3,937,500 shares of its common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share.

19 Oct 2009

Durham VA Medical Center receives Daxor's BVA-100 Blood Volume Analyzer

Daxor Corporation, a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from the Institute for Medical Research at the Durham Veterans Affairs (VA) Medical Center of Durham, North Carolina.

19 Oct 2009

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

Amarin Corporation plc today announced that it has executed an agreement with Medpace, Inc. (‘Medpace’), a leading Contract Research Organization (CRO) with expertise in conducting clinical trials in cardiovascular and metabolic disease, to engage their services in the execution of its Phase 3 clinical trials with AMR101 in patients with very high triglyceride levels (the AMR101 MARINE Study) and mixed dyslipidemia.

19 Oct 2009

Amgen receives Complete Response Letter for the Biologic License Applications for Prolia from FDA

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis.

19 Oct 2009

Lux Biosciences raises $50 million through Series B venture financing

Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company has closed a $50 million Series B venture financing. Participants in the funding were current investors in Lux Biosciences, HBM Bioventures, Novo A/S, Prospect Venture Partners and SV Life Sciences (SVLS), as well as SVLS' publicly traded fund, International Biotechnology Trust plc.

19 Oct 2009

Sigma-Aldrich launches SAGEspeed, a program for developing human disease models in rodents

Sigma-Aldrich® (Nasdaq: SIAL) today announced the launch of SAGEspeed(TM), a program to develop human disease models in rodents using its proprietary novel CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (http://www.compozrzfn.com).

19 Oct 2009

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.

19 Oct 2009

Arigene to purchase all outstanding shares of common stock of Trimeris

Arigene Co., Ltd., a Korean corporation traded on the Korean Securities Dealers Association Quotation System, through its wholly-owned subsidiary, RTM Acquisition Company, a Delaware corporation, today commenced a cash tender offer to purchase all outstanding shares of common stock of Trimeris, Inc., a Delaware corporation, pursuant to the Agreement and Plan of Merger among Arigene, RTM Acquisition Company and Trimeris, executed and publicly announced on October 2, 2009.

19 Oct 2009

Viriom picks ChemDiv's Russian subsidiary for development of innovative HIV compounds

ChemDiv, Inc. of San Diego has proudly announced that its wholly owned subsidiary Chemical Diversity Research Institute (CDRI ) of Moscow, Russia, has been chosen by Viriom Ltd. ( Viriom) of Moscow, Russia as a service partner in developing innovative HIV compounds. The program includes pre-clinical and clinical studies, which are expected to begin in 2010.

19 Oct 2009

Talecris Biotherapeutics' PROLASTIN-C receives FDA approval

Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of PROLASTIN® produced using advances in manufacturing technology.

19 Oct 2009

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Genentech, Inc., a wholly-owned member of the Roche Group, today announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent).

19 Oct 2009

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

Biotechnology News and Research

ImmunoCellular Therapeutics files a provisional patent application

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Biomagnetics Diagnostics to raise $1 million

RA patients who adhere to their prescription drug regimen have better outcome: Study

Patheon, Lonza Group mutually agree to terminate discussions

Bio-Bridge Science receives business license for Bio-Bridge JRS Biosciences (Beijing)

PhRMA report says nearly 1,000 life-changing medicines for diseases affecting women in development

Medidata Solutions extends multi-year contract with Bristol-Myers Squibb

Encorium Group raises $1.6 million through private placement

Durham VA Medical Center receives Daxor's BVA-100 Blood Volume Analyzer

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

Amgen receives Complete Response Letter for the Biologic License Applications for Prolia from FDA

Lux Biosciences raises $50 million through Series B venture financing

Sigma-Aldrich launches SAGEspeed, a program for developing human disease models in rodents

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Arigene to purchase all outstanding shares of common stock of Trimeris

Viriom picks ChemDiv's Russian subsidiary for development of innovative HIV compounds

Talecris Biotherapeutics' PROLASTIN-C receives FDA approval

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Angiochem reports Phase 1/2 efficacy study results of ANG1005 for treating brain cancer

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News